5 completed, 3 terminated. 4 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow cilofexor: new trials by email Literature Review of cilofexor trials Research Report on cilofexor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Gilead Sciences | 457 | 2021-08-09 | 2025-11-26 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Cilofexor - Primary Sclerosing Cholangitis, Compensated Cirrhosis | Phase 1 | Terminated | Gilead Sciences | 11 | 2019-10-17 | 2023-07-27 |
| Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Semaglutide, Firsocostat, Cilofexor - Nonalcoholic Steatohepatitis | Phase 2 | Completed | Gilead Sciences | 109 | 2019-07-29 | 2021-07-15 |
| Study of Cilofexor in Adults With Primary Sclerosing Cholangitis Cilofexor, Placebo - Primary Sclerosing Cholangitis | Phase 3 | Terminated | Gilead Sciences | 419 | 2019-03-27 | 2023-11-29 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Cilofexor, Placebo to match cilofexor - Primary Biliary Cholangitis | Phase 2 | Terminated | Gilead Sciences | 71 | 2016-12-01 | 2020-09-22 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Cilofexor, Placebo to match cilofexor - Primary Sclerosing Cholangitis | Phase 2 | Completed | Gilead Sciences | 52 | 2016-11-29 | 2021-06-07 |
| Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Cilofexor - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Gilead Sciences | 57 | 2016-07-13 | 2021-01-07 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics Cilofexor, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Gilead Sciences | 120 | 2016-01-20 | 2020-10-12 |
Cholangitis, Sclerosing (4) · Non-alcoholic Fatty Liver Disease (4) · Liver Cirrhosis, Biliary (1)
Gilead Sciences (8)
United States (8) · Canada (4) · Austria (3) · United Kingdom (3) · Australia (2) · France (2) · Japan (2) · New Zealand (2) · Spain (2) · Belgium (1) · Denmark (1) · Finland (1) · Germany (1) · Israel (1) · Italy (1)
PMID 30661255, PMID 35439567, PMID 38976363, PMID 41173015
2016 (2), 2019 (1)